ESTIMATION ON CLINICAL JUSTIFICATION FOR THE ESTABLISHMENT OF COPPER-64 RADIOISOTOPE PRODUCTION AND COPPER-64 RADIOPHARMACEUTICALS APPLICATION
Keywords:
copper‑64, cancer incidence, cancer mortality, positron emission tomography, radiopharmaceuticalsAbstract
Establishing the production of radiopharmaceuticals and introducing new radiopharmaceuticals into healthcare practice in a developing country is challenging, primarily from an economic point of view. A feasibility study provides an objective assessment that takes into account not only the economic aspect but also the clinical impact and development of research potential. The first phase of the feasibility study for the establishment of copper-64 radioisotope production is a preliminary analysis, which aims to assess whether the introduction of 64Cu-radiopharmaceuticals into clinical use is possible and justified. The preliminary analysis includes a review of statistical data on malignant diseases on a national level based on reference databases, international and domestic, and a review of data on the clinical application of 64Cu-radiopharmaceuticals based on a reference database for clinical trials. As to the cancer statistics review, for a more objective insight into assessing the justification for introducing new radiopharmaceuticals into clinical use, data on malignancies in North Macedonia were compared with data related to the world, southern Europe and the European Union. The comparison focused on data relating to lung, cervical, and brain neoplasms as cancers examined in clinical trials involving [64Cu][Cu(ATSM)] radiopharmaceutical, one of the most widely explored 64Cu-radiopharmaceuticals. As can be seen from the comparison, cervical cancer has a lower incidence and mortality in Macedonia than in the world but a higher incidence and mortality compared to southern Europe and the countries of the European Union. Lung and brain cancers have a higher incidence and mortality in Macedonia than in all other compared regions. The results of the cancer statistic review indicate that it is rational to adopt strategies which can contribute to better management of malignant diseases in Macedonia. One of those potential strategies could be introducing new radiopharmaceuticals in nuclear medicine practice. As for solid malignant tumors, the detection of tumor hypoxia is of particular importance to optimize the treatment strategy and improve the overall prognosis. Positron emission tomography with hypoxia-avid radiopharmaceutical is a noninvasive method for measuring hypoxia, highly sensitive and directly quantitative. Considering the results of the preliminary analysis, it is reasonable to proceed to the next stages of the feasibility study for the establishment of the production of 64Cu radioisotope and the implementation of 64Cu-radiopharmaceuticals in clinical practice in Macedonia. Radiopharmaceuticals based on copper-64 radioisotope are promising due to the unique properties of this radionuclide that are complementary for diagnostic and/or therapeutic purposes.
References
Bourgeois, M., Rajerison, H., Guerard, F., Mougin-Degraef, M., Barbet, J., Michel, N., Cherel, M., & Faivre-Chauvet, A. (2011). Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review. Nuclear medicine review. Central & Eastern Europe, 14(2), 90–95.
Global Cancer Observatory (GCO), International Agency for Research on Cancer (IARC), 2021. Population Fact Sheets.
Gutfilen, B., Souza, S. A., & Valentini, G. (2018). Copper-64: a real theranostic agent. Drug design, development and therapy, 12, 3235–3245.
Institute of Public Health of Republic North Macedonia (IPH), 2021. Cancer Register. Cancer in the Republic of North Macedonia, 2011-2020.
Institute of Public Health of Republic North Macedonia (IPH), 2021. Mortality Register. Mortality in Republic North Macedonia 2020.
INTERNATIONAL ATOMIC ENERGY AGENCY. (2022). Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications. IAEA, Vienna
Jalilian, A. R., & Osso Jr, J. (2017). The current status and future of theranostic Copper-64 radiopharmaceuticals. Iranian Journal of Nuclear Medicine, 25(1), 1-10.
Li, Y., Zhao, L., & Li, X. F. (2021). Hypoxia and the Tumor Microenvironment. Technology in cancer research & treatment, 20, 15330338211036304.
Liu, T., Karlsen, M., Karlberg, A. M., & Redalen, K. R. (2020). Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms. EJNMMI research, 10(1), 33.
Lopci, E., Grassi, I., Rubello, D., Colletti, P.M., Cambioli, S., Gamboni, A., Salvi, F., Cicoria, G., Lodi, F., Dazzi, C., Mattioli, S., & Fanti, S. (2016). Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. Clinical Nuclear Medicine, 41, e87–e92.
Nishikawa, Y., Takahashi, N., Nishikawa, S., Shimamoto, Y., Nishimori, K., Kobayashi, M., Kimura, H., Tsujikawa, T., Kasuno, K., Mori, T., Kiyono, Y., Okazawa, H., & Iwano, M. (2023). Feasibility of Renal Blood Flow Measurement Using 64Cu-ATSM PET/MRI: A Quantitative PET and MRI Study. Diagnostics (Basel, Switzerland), 13(10), 1685.
Okazawa, H., Ikawa, M., Tsujikawa, T., Mori, T., Makino, A., Kiyono, Y., Nakamoto, Y., Kosaka, H., & Yoneda, M. (2022). Cerebral Oxidative Stress in Early Alzheimer's Disease Evaluated by 64Cu-ATSM PET/MRI: A Preliminary Study. Antioxidants (Basel, Switzerland), 11(5), 1022.
Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209- 249.
Xie, F., & Wei, W. (2022). [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation. European journal of nuclear medicine and molecular imaging, 49(12), 3964–3972.
Zhou, Y., Li, J., Xu, X., Zhao, M., Zhang, B., Deng, S., & Wu, Y. (2019). 64Cu-based Radiopharmaceuticals in Molecular Imaging. Technology in cancer research & treatment, 18, 1533033819830758.
